Parkinson's Disease (PD) is a progressive neurodegenerative disorder that predominantly affects the dopaminergic neurons in the substantia nigra, causing motor and non-motor symptoms. The pathogenesis of PD is multifactorial, involving genetic and environmental factors. This complex disorder requires a comprehensive understanding for optimal patient management.
PD affects approximately 1% of individuals over the age of 60, with a higher prevalence in males. Risk factors include age, genetic predisposition, exposure to certain pesticides, and history of head injury. Conversely, caffeine intake and tobacco use appear to have a protective effect.
The hallmark of PD is the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to dopamine deficiency in the striatum. This results in an imbalance in the direct and indirect pathways of the basal ganglia, causing motor symptoms. The presence of Lewy bodies, composed of alpha-synuclein, is another characteristic feature.
PD presents with both motor (bradykinesia, rigidity, rest tremor, postural instability) and non-motor symptoms (depression, constipation, sleep disturbances). Diagnosis is primarily clinical, supported by response to dopaminergic therapy. Neuroimaging can aid in differentiating PD from other parkinsonian syndromes.
Treatment of PD is symptomatic, with levodopa being the most effective medication for motor symptoms. Non-motor symptoms are managed with a multidisciplinary approach. Deep brain stimulation can be considered in patients with motor complications not adequately controlled by medication.
PD is a complex neurodegenerative disorder with a multifactorial pathogenesis. A comprehensive understanding of its epidemiology, pathophysiology, clinical presentation, and treatment options is essential for healthcare professionals to provide optimal patient care.
1.
Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions
2.
Sevabertinib Approved for First-Line Mutated NSCLC
3.
After three years, responses to mounetuzumab in follicular lymphoma are still stable.
4.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
5.
AI can identify women at risk of breast cancer years in advance: Study
1.
Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy
2.
Pediatric Tumor Microenvironment Evolution: Mechanisms, Clinical Impact, and Therapeutic Implications
3.
Hematopoietic Stem Cell Activity Biomarkers in Aging
4.
Bone-Marrow Immune Cell Competition: Mechanisms, Clinical Implications, and Emerging Therapeutic Perspectives
5.
The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Emerging Concepts in Hematology
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation